Breast Cancer Indexbciis A Proprietary Genomic Test Developed By Biotheranostics And Associated With Hologicthis Test Is Designed To Assist In Making Informed Decisions About The Duration Of Endocrine Therapy For Breast Cancer Patientsit Is Recognized In The Asco Clinical Practice Guideline For Its Utility In Clinical Settings The Primary Service Of The Breast Cancer Index Involves Analyzing Genomic Markers To Predict The Likelihood Of Cancer Recurrence And The Potential Benefits Of Extended Endocrine Therapythis Information Aids Healthcare Providers And Patients In Discussing And Determining The Most Appropriate Treatment Durationthe Test Results Are Presented In A Clear Reportfacilitating Effective Communication About Treatment Plans
